ReviewAntimicrobial agents and chemotherapy2017
Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance.
Review in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 211 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
211 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Evaluating the efficacy of the praziquantel dose pole for schistosomiasis treatment: A multi-country systematic review.PLoS neglected tropical diseases · 2025Pooled it
- Praziquantel efficacy, urinary and intestinal schistosomiasis reinfection - a systematic review.Pathogens and global health · 2023Pooled it
- Differential impact of mass and targeted praziquantel delivery on schistosomiasis control in school-aged children: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2019Pooled it
- Comparative palatability of orally disintegrating tablets (ODTs) of Praziquantel (L-PZQ and Rac-PZQ) versus current PZQ tablet in African children: A randomized, single-blind, crossover study.PLoS neglected tropical diseases · 2021Trial
- The Impact of Intensive Versus Standard Anthelminthic Treatment on Allergy-related Outcomes, Helminth Infection Intensity, and Helminth-related Morbidity in Lake Victoria Fishing Communities, Uganda: Results From the LaVIISWA Cluster-randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Trial
- Effect of Artemisia annua and Artemisia afra tea infusions on schistosomiasis in a large clinical trial.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2018Trial
- StandardizedPathogens (Basel, Switzerland) · 2026Article
- Mapping therapeutic alternatives: a systematic review of preclinical drug repurposing for schistosomiasis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- IL-22 modulates STAT3/β-catenin/let-7a signaling and hepatic granulomas in Schistosoma mansoni infection: versus praziquantel and combination treatment.Molecular biology reports · 2026Article
- No Simple Fluke: Schistosomiasis as an Emerging Regulator of Haematopoiesis.Parasite immunology · 2026Review
- Safranal Enhances the Efficacy of Praziquantel AgainstJournal of xenobiotics · 2026Article
- Strevertene A, a Streptomyces-Derived Macrolide, Reveals Selective Activity against the Human ParasiteACS omega · 2026Article
- Long Non-Coding RNAs Identified as Hub Genes by Weighted Gene Co-Expression Network Analysis inInternational journal of molecular sciences · 2026Article
- Schistosoma japonicum histone acetyltransferase 1 (SjHAT1): A novel anti-schistosomal drug target.PLoS pathogens · 2026Article
- Plant-Derived Terpenes as Emerging Therapeutics Against Schistosomiasis.International journal of molecular sciences · 2026Review
- Use of a cytochrome P450 humanized mouse model to refine schistosomiasis drug discovery.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Article
- ComprehensiveNon-coding RNA · 2026Article
- Thiazole as a Promising Scaffold for the Treatment of Schistosomiasis: In Vitro and In Vivo Activity Against Different Developmental Stages ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Biological Activity of Stilbenoids Against Fungal, Parasitic, and Viral Pathogens.Molecules (Basel, Switzerland) · 2026Review
151 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Schistosomiasis, a major neglected tropical disease, affects more than 250 million people worldwide. Treatment of schistosomiasis has relied on the anthelmintic drug praziquantel (PZQ) for more than a generation. PZQ is the drug of choice for the treatment of schistosomiasis; it is effective against all major forms of schistosomiasis, although it is less active against juvenile than mature parasites. A pyrazino-isoquinoline derivative, PZQ is not considered to be toxic and generally causes few or transient, mild side effects. Increasingly, mass drug administration targeting populations in sub-Saharan Africa where schistosomiasis is endemic has led to the appearance of reduced efficacy of PZQ, which portends the selection of drug-resistant forms of these pathogens. The synthesis of improved derivatives of PZQ is attracting attention, e.g., in the (i) synthesis of drug analogues, (ii) rational design of pharmacophores, and (iii) discovery of new compounds from large-scale screening programs. This article reviews reports from the 1970s to the present on the metabolism and mechanism of action of PZQ and its derivatives against schistosomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.